drugset / Trial / NCT07131514
HRS-4642 in Combination With Gemcitabine and Albumin-bound Paclitaxel and Adebrelimab for Neoadjuvant and Adjuvant Treatment of Pancreatic Cancer
NaSingle-groupOpen-labelTreatment
Summary
To evaluate the safety and efficacy of HRS-4642 in Combination With AG and Adebrelimab for Neoadjuvant and Adjuvant Treatment of Pancreatic Cancer
Timeline
- Start
- 2025-08-25
- Primary completion
- 2027-06
- Completion
- 2027-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HRS-4642 | Unknown | — | — |
| Background | Adebrelimab | Monoclonal antibody | — | — |
| Background | Albumin-Bound Paclitaxel | Unknown | — | — |
| Background | Gemcitabine | Small molecule | — | — |